When to Use Breast Cancer Index

Susan K Boolbol, MD
Stephen C. Malamud, MD
Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss the circumstances in which they would use the Breast Cancer IndexSM(BCI) to assist in determining whether to extend the adjuvant therapy of women with breast cancer beyond 5 years.
Related Articles
Overcoming Challenges to Molecular Biomarker Testing
Geoff Oxnard, MD, Lauren Ritterhouse, MD, PhD
|
Video Library
Drs. Geoffrey Oxnard and Lauren Ritterhouse discuss the challenges in biomarker testing—tissue stewardship and complexity of biomarker tests and results—and ways to overcome these challenges—improved communication among all members of the cancer care team and simplification of biomarker test results to focus on actionable biomarkers.
Impact of Reimbursement for Biomarker Testing on Clinical Practice
Geoff Oxnard, MD, Lauren Ritterhouse, MD, PhD
|
Video Library
Drs. Geoffrey Oxnard and Lauren Ritterhouse deliberate on ways reimbursement issues are impacting clinical practice, particularly CMS’s “14-Day Rule.”
Reimbursement Challenges and Solutions with Molecular Biomarker Testing
Geoff Oxnard, MD, Lauren Ritterhouse, MD, PhD
|
Video Library
Drs. Geoffrey Oxnard and Lauren Ritterhouse consider the current landscape of reimbursement for molecular biomarker testing, the need to run FDA-approved tests, and the role of CMS and local Medicare providers in testing reimbursement.
Last modified: June 10, 2018

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code
X